Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

723O Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: Final results of the PEGASUS trial

Among patients with two consecutive post-surgical negative tests, 12 relapses occurred, for a 2-year no-evidence-of-disease rate of 88% (90% CI 81-93). The predefined feasibility threshold (fewer than 14 relapses among 134 negative patients to exclude 85% in favor of 92%) was not met, though the point estimate exceeded 85%. In the 35 positive patients, 13 (37%) relapsed; 2-year time-to-relapse was 87.6% vs 61.5% (HR 3.22, P=0.0013).

ESMO Congress 2025